Capricor shares four-year data showing Deramiocel slowed DMD progression and preserved function, with maintained safety in long-term use.

Capricor Therapeutics (NASDAQ:CAPR) lost ~15% on Friday after the cell therapy developer posted long-term data from an ...

Sarepta shares face pressure after a second Elevidys-linked death and analyst downgrade over safety concerns and lowered ...

The ouster of the FDA's chief regulator of cell and gene therapies came immediately after a disagreement with her boss over a ...

Travis Kelce and Patrick Mahomes hosted Make-A-Wish kids at Kansas City Chiefs practice, offering gifts and unforgettable ...

Caregiving means that columnist Betty Vertin sometimes misses out on activities with her children who don't have DMD. Finding balance is key.

Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise ...

Four-year data show preservation of cardiac function, including LVEFSkeletal muscle disease progression continues to slow ...

Fintel reports that on June 20, 2025, William Blair downgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

New York Yankees captain Aaron Judge is one of the scariest hitters in the league but not the scariest on the team, according ...

Two young brothers from Brooklyn who have muscular dystrophy were honored on Thursday at Yankee Stadium for the annual Hope ...